EUCTR2008-008376-14-IT进行中（未招募）不适用
A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF COMBINED TREATMENT OF GUGGULU AND TRIPHALA FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND OVERWEIGHT IN SUBJECTS NOT SUITABLE FOR THERAPY WITH STATINS - TRIGU PROJECT
AZIENDA ASL BRESCIA0 个研究点开始时间: 2009年3月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Ø Males and females 35-65 years of age Ø Total serum cholesterol 200-300 mg/dl Ø BMI > 25 and < 35 Ø Global cardiovascular risk: < 20% of events expected in next 10 years Ø Willingness to participate in and comply with the study Ø Willingness to give informed consent Ø Willingness to prevent conception during the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Ø Documented hypersensitivity to the study treatment or its excipients Ø History of ischaemic heart disease Ø History of diabetes mellitus Ø Global cardiovascular risk: >= 20% of events expected in next 10 years and/or statin treatment Ø Presence of a severe chronic disease Ø Chronic therapy with any drug Ø Pregnancy or breast feeding
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to study the effects of 300mg of Inclisiran sodium given as subcutaneous injection in subjects with an inherited disorder, known as Heterozygous familial Hypercholesterolemia, that causes elevated blood cholesterol levels (LDL-Cholesterol)MedDRA version: 20.1 Level: LLT Classification code 10020604 Term: Hypercholesterolemia System Organ Class: 100000004861HypercholesterolemiaEUCTR2017-002472-30-SEThe Medicines Company400
进行中（未招募）
1 期
A clinical trial to study the effects of 300mg of Inclisiran sodium given as subcutaneous injection in subjects with an inherited disorder, known as Heterozygous familial Hypercholesterolemia, that causes elevated blood cholesterol levels (LDL-Cholesterol)MedDRA version: 20.1Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861HypercholesterolemiaEUCTR2017-002472-30-GBThe Medicines Company482
进行中（未招募）
1 期
A clinical trial to study the effects of 300mg of Inclisiran sodium given as subcutaneous injection in subjects with an inherited disorder, known as Heterozygous familial Hypercholesterolemia, that causes elevated blood cholesterol levels (LDL-Cholesterol)MedDRA version: 20.1 Level: LLT Classification code 10020604 Term: Hypercholesterolemia System Organ Class: 100000004861HypercholesterolemiaEUCTR2017-002472-30-CZThe Medicines Company400
进行中（未招募）
1 期
A clinical trial to study the effects of 300mg of Inclisiran sodium given as subcutaneous injection in subjects with an inherited disorder, known as Heterozygous familial Hypercholesterolemia, that causes elevated blood cholesterol levels (LDL-Cholesterol)MedDRA version: 20.0 Level: LLT Classification code 10020604 Term: Hypercholesterolemia System Organ Class: 100000019513HypercholesterolemiaEUCTR2017-002472-30-ESThe Medicines Company400
进行中（未招募）
1 期
A clinical trial to study the effects of 300mg of Inclisiran sodium given as subcutaneous injection in subjects with an inherited disorder, known as Heterozygous familial Hypercholesterolemia, that causes elevated blood cholesterol levels (LDL-Cholesterol)MedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861HypercholesterolemiaEUCTR2017-002472-30-DKThe Medicines Company400